Taken together, we speculate that PRL and bone metabolism markers may be related to the underlying mechanisms of reduced BMD in male chronic schizophrenia patients, thus providing a useful viewpoint to monitor the bone health of male schizophrenia patients on long term antipsychotics treatment. This evidence concerns the gene PRL and schizophrenia.